Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) Net Margin (2020 - 2025)

Foghorn Therapeutics (FHTX) has 5 years of Net Margin data on record, last reported at 682.88% in Q4 2024.

  • For Q4 2024, Net Margin fell 26502.0% year-over-year to 682.88%; the TTM value through Sep 2025 reached 79.55%, up 27798.0%, while the annual FY2024 figure was 383.24%, 9507.0% down from the prior year.
  • Net Margin reached 682.88% in Q4 2024 per FHTX's latest filing, down from 244.9% in the prior quarter.
  • Across five years, Net Margin topped out at 82.07% in Q3 2023 and bottomed at 65268.29% in Q3 2021.
  • Average Net Margin over 5 years is 6145.46%, with a median of 645.59% recorded in 2022.
  • Peak YoY movement for Net Margin: tumbled -5482639bps in 2021, then surged 6487985bps in 2022.
  • A 5-year view of Net Margin shows it stood at 8406.37% in 2020, then soared by 52bps to 3998.32% in 2021, then skyrocketed by 83bps to 690.39% in 2022, then skyrocketed by 39bps to 417.85% in 2023, then crashed by -63bps to 682.88% in 2024.
  • Per Business Quant database, its latest 3 readings for Net Margin were 682.88% in Q4 2024, 244.9% in Q3 2024, and 333.61% in Q2 2024.